

ORIGINAL
ARTICLE

Comparison of Two Recombinant Hepatitis B Vaccines

Hasan Nikui Nejad ¹, Gholamali Ghorbani ^{2*}, Reza Razaghi ³, Hossain Akbari ³¹ Tehran University of Medical Sciences, Tehran, Iran² Health Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran³ Kashan University of Medical Sciences, Kashan, Iran

Background and Aims: Hepatitis B virus (HBV) infection is an important public health problem. Hepatitis B vaccine induces protective response in the majority of vaccinated persons. In our country, we do not have any evaluation for the efficacy of each type of vaccines used in adult and our objective was therefore to evaluate the efficacy of vaccines.

Methods: In a randomized double-blind clinical trial 347 military personnel and their family in Kashan city, central Iran, were studied during August 2007 to April 2008. Participates who did not have history of HBV vaccination were included in this study. Five-mL blood samples were taken from each person and tested for hepatitis B surface antigen (HBsAg), hepatitis B surface antibody (HBsAb) and total hepatitis B core antibody (HBcAb). If the test results were negative, they were then divided into two groups and vaccinated with either recombinant Cuban or Korean vaccine. One month after the latest vaccine dose, we assessed the antibody to hepatitis B surface antigen (anti-HBs Ab) titer.

Results: 347 subjects (207 men, 140 women) were studied. All participants were more than 15 years old. The mean±SD age of participants was 32.3±7.2 years. The mean±SD titer of anti-HBs Ab was 253.6±95.4 MIU/mL in Cuban group and 315.7±163.5 in Korean vaccine group (P<0.001). The Korean vaccine induced a higher titer of antibody in ages less than 40. Four (2.3%) subjects in the Cuban and 2 (1.1%) in the Korean vaccine group did not develop protection.

Conclusions: The Korean vaccine induces more protection and higher titer in subjects aged less than 40 years than the Cuban vaccine. Therefore, we believe that the Korean hepatitis B vaccine is a better choice in comparison to the Cuban vaccine for prevention of hepatitis B virus infection and mass vaccination in our country.

Keywords: Hepatitis B Vaccine, Hepatitis B Virus, Heberbiovac-HB

Introduction

Hepatitis B virus (HBV) infection is an important public health problem in the world. Recent estimates has shown that more than two billion people are infected with HBV globally and that the infection is supposed to be causally related to one to two million deaths per year worldwide. More than 350 million people are chronic carriers of HBV (1). Prior to the implementation of vaccination programs, the lifetime risk of HBV infection exceeded 60% in areas with high prevalence of the disease, such as China, Southeast Asia, and Africa (2). Hepatitis B vaccination has been one of the success stories of the 20th century and has been extensively used in a wide range of groups throughout the world and it has successfully reduced the prevalence of hepatitis B infection (3). Three different classes of

hepatitis B vaccine are available based upon how they are derived (*i.e.* from plasma, yeast, or mammalian cells). The first generation HBV vaccine was prepared by concentrating and purifying plasma from hepatitis B surface antigen (HBsAg) carriers. This vaccine has excellent efficacy and safety.

* Correspondence:

Gholamali Ghorbani, M.D.

Assistant Professor of Infectious Diseases, Health Research Center, Baqiyatallah University of Medical Sciences, Mollasadra St., Tehran, Iran.

Tel/Fax: +98 21 8860 0062

E-mail: gholamalighorbani@yahoo.com

Received: 7 Oct 2008

Revised: 21 Nov 2008

Accepted: 10 Dec 2008

Hepat Mon 2009; 9 (3): 201-205

However, it suspected to transmit blood-borne infections. As a result, it is no longer used in most developed countries ^(4, 5).

The second generation HBV vaccine is yeast-derived recombinant vaccines. They are produced by cloning of the HBV S gene in yeast cells. The recombinant vaccines contained thimerosal as a preservative. Then, two yeast-derived recombinant thimerosal-free vaccines have been developed (Recombivax HB and Engerix-B) which are widely available ^(6, 7).

The third class of HBV vaccine is the mammalian cell-derived recombinant vaccine. Three vaccines of this class have been developed. In addition to the S antigen, one of these contains antigen from the pre-S₂ region while the other two contain antigens from both the pre-S₁ and pre-S₂ regions. Although vaccines with pre-S antigen may have more immunogenicity they are not widely available. Currently, vaccination is one of the most important preventive measures for HBV infection ^(8, 9).

In Iran, the prevalence of chronic carrier state of hepatitis B infection has been reported to be 2.5%-3%. The rate has been reduced since establishment of the National HBV vaccination program in 1993 for all neonates ⁽¹⁰⁾ and high risk groups of adults such as military personnel ⁽¹¹⁾. In our country, we first used plasma derived vaccine and then recombinant vaccine ^(12, 13). Hepatitis B vaccines induce protective response in the majority of vaccinated persons, however, 1%-10% of both adults and neonates fail to response depending on the use of differ recombinant vaccines, as one factor. We do not have any comparative study on efficacy of each type of HBV vaccines imported from other countries such as Cuba (Heberbiovac HB vaccine) and Korea (Hepavax-Gene vaccine). The objective of this study was to investigate the effect of Cuban (Heberbiovac HB) and Korean (Hepavax-Gene) vaccines in adult and middle-aged persons after three doses of each vaccine.

Materials and Methods

A randomized double-blind clinical trial was conducted on military personnel and their family in Kashan, Isfahan province, Central Iran during August 2007-April 2008. Those people who did not have any history of HBV vaccination, HBV infection, use of immunosuppressive agent, HIV infection, steroid therapy, addiction and acute viral infection at the time of vaccination, were included in this study. Participants gave informed written consents prior to the administration of the vaccine.

This project was approved by the Ethics Committee of Research Departments of Baqiyatallah University of Medical Sciences (project No: 87-481-June-2008 of Health Research Center). In the calculation of the sample size of 328 (164 samples for each vaccine), we assumed an expected seroprotection rate of more than 96% in hepatitis B vaccinated persons in Iran ⁽¹³⁾. Demographic data collected from each person included age and level of education. Five-mL blood samples were taken from each participant and assessed for HBsAg, hepatitis B surface antibody (HBsAb) and total hepatitis B core antibody (HBcAb); if the test results were negative, then the participants were vaccinated. HBsAb, HBsAg and HBcAb were assessed with enzyme-linked immunosorbent assay (ELISA; Equipar, Italy). The participants were divided into two randomized groups and vaccinated with adult dose of 20 µg of HBsAg with either recombinant Cuban (Heberbiovac HB, Heberbiotec, Havana, Cuba) or Korean (Hepavax-Gene, Green Cross vaccine Corp, Korea) vaccine. One mL of each of these vaccines contains 20 µg of purified HBsAg, 0.5 mg aluminum hydroxide and 0.05 mg thiomersal.

The vaccines were administered intramuscularly in the deltoid muscle on 0, 1, and 6 months. One month after the last dose, we assessed the antibody to hepatitis B surface antigen (anti-HBs Ab) titer. Titers equal or more than 10 MIU/mL were considered as appropriate immune response and "protection"; titers below 10 MIU/mL were considered as seroconversion but "no protection". Side effects after vaccination such as fever, local pain, allergic reaction, erythema and local cellulites were recorded.

Statistical analyses were done with the SPSS® v.13 for Windows®. Rates of seroconversion or seroprotection were compared between each group by two-tailed Fisher's exact test and χ^2 . Mann-Whitney U test was used for comparison of means between the two groups. $P < 0.05$ was considered statistically significant.

Results

During the study period, we studied 347 (207 male, and 140 female) military personnel and their families. The mean±SD age of participants was 32.3±7.2 (range: 15-51) years; 295 (85%) of persons were less than 40 years old. Most of participants (n=217, 62.5%) had diploma or less; the remaining had at least a bachelor degree. Heberbiovac HB Cuban vaccine was given to 172 (49.6%) and Hepavax-Gene Korean vaccine was administered to 175 (50.4%) persons. The

geometric mean \pm SD of the anti-HBs Ab titer was 253.6 \pm 95.4 (95% CI: 0.9-310.8) MIU/mL in Heberbiovac HB Cuban vaccine group and 315.7 \pm 163.5 (95% CI: 4.1-666.4) MIU/mL in Hepavax-Gene Korean vaccine group ($P<0.001$). Anti-HBs Ab titer in the Korean vaccine had a significant correlation with age and was higher in those less than 40 years of age. Four (2.3%) persons from the Cuban vaccine group and two (1.1%) from the Korean vaccine group failed to produce the minimum acceptable antibody level (Table 1). While men more responsive to the Cuban vaccine, women had a higher response to the Korean vaccine (Table 1). No side effects but mild local pain was

Table 1. The geometric mean \pm SD (MIU/mL) antibody titers in the Cuban and Korean HBV vaccines.

	Cuban vaccine	Korean vaccine	P-value
Men	263.2 \pm 90.8	307.7 \pm 145.3	0.015
Women	228.1 \pm 103.1	322.8 \pm 178.6	<0.001
Age<40 years	257.9 \pm 90.6	323.5 \pm 164.7	<0.001
Age \geq 0years	238.5 \pm 110.5	226.4 \pm 120.9	0.74
Non-responders	4 (2.3%)	2 (1.1%)	0.439

observed.

Discussion

Our finding that the Korean Hepavax-Gene vaccine and the Cuban Heberbiovac HB vaccine, respectively, produced protection in almost 99% and more than 97% of people, is similar to results of other studies⁽¹⁴⁾.

These two vaccines were highly efficient in antibody production, though less than 2% of participants were unresponsive. Another study reported about 5%-10% of unresponsiveness. This difference in the immunogenicity amongst the recombinant vaccines is primarily due to the differences in strain source, production, and protein purification protocols employed by the manufacturers⁽¹⁵⁾. Those who failed to produce the protective antibody level may be protected with an additional dose of the vaccine⁽¹⁶⁾.

The immune response is influenced by the dosage and time of evaluation after completing the vaccination. Therefore, although the response in short-term might be similar, it is necessary to evaluate the long-term response⁽¹⁵⁾.

This study showed that the Korean Hepavax-Gene vaccine induced a significantly higher antibody titer than the Cuban Heberbiovac HB vaccine. This finding was different from the results

of Baldy that indicated that the Korean Hepavax-Gene vaccine with induction of high antibody titer may produce long-term protection⁽¹⁴⁾.

We showed that gender had some effects on the response to vaccine; women and men who were vaccinated with the Korean vaccine developed a significantly ($P<0.05$) higher antibody titers than those who received the Cuban vaccine. This is in contrary to the findings of most of other studies. This difference may be due to the type of vaccine administered and younger age of persons in their studies^(17, 18). Similar results were reported by Janbakhsh *et al.*⁽¹⁹⁾ which showed a response rate of 74.7% in male and 61.8% of female healthcare workers and also in a study conducted in Yazd province, Iran, which may be due to the less effectiveness of Heberbiovac HB than other similar vaccines⁽²⁰⁾.

We showed that vaccination with each type of the vaccines in ages less than 40 years induced a significantly higher titer and protection. The Korean Hepavax-Gene vaccine was also more effective than Heberbiovac HB Cuban vaccine in ages less than 40. Similar to other reports its difference was not significant in ages more than 40, which warrants addition of an added dose or a booster dose for better response in older ages⁽²¹⁻²⁴⁾. Amongst all risk factors, higher age was the most important factor, as shown by declining in seroprotection rates⁽¹⁵⁾ which may be due to cellular defects. Therefore, people should be immunized before age of 40^(19, 25-27).

The Hepavax-Gene Korean vaccine induces more protection than Heberbiovac HB Cuban vaccine and therefore vaccination with Korean may be more effective than the Cuban vaccine⁽²⁸⁾.

Hepatitis B vaccination, as part of extended program of immunization (EPI), is free of charge for children in Iran but the vaccines should be imported from other countries by the Ministry of Health. The cost of HBV vaccine is important in developing countries such as Iran; here, the price of one dose of Hepavax-Gene Korean vaccine is cheaper than one dose of Heberbiovac HB Cuban vaccine and that is why we think the Korean vaccine is better for mass vaccination^(28, 29).

No local or systematic adverse reactions after vaccination were observed and the two vaccines studied are safe, as shown in another study⁽²⁴⁾. Some reported adverse reactions in other studies with Hepavax-Gene vaccine may be due to thiomerosal preservative of this vaccine^(30, 31).

One of the limitations of this study was the small sample size we studied. Therefore, conduction of a study with a larger sample sizes is warranted, although finding a large sample size of high risk

group adults who have not been vaccinated is very difficult in Iran.

Conclusions

This study showed that there is significant difference between these two types of vaccines, and Hepavax-Gene Korean vaccine had more protective effect, higher geometric titer in men, women and individuals under forty of age than Heberbiovac HB Cuban vaccine. Korean vaccine also is cheaper than Cuban vaccine and therefore we think that Hepavax-Gene Korean vaccine is the best choice for prevention of HBV infection and mass vaccination in Iran.

Acknowledgements

We thank the Health Research Center of Baqiyatallah University of Medical Sciences and also the Health Center of Air Force in Kashan for contribution to this study.

References

- Shivananda, Somani V, Srikanth BS, Mohan M, Kulkarni PS. Comparison of two hepatitis B vaccines (GeneVac-B and Engerix-B) in healthy infants in India. *Clin Vaccine Immunol*. 2006 Jun;13(6):661-4.
- La Torre G, Nicolotti N, de Waure C, Chiaradia G, Specchia ML, Mannocci A, *et al*. An assessment of the effect of hepatitis B vaccine in decreasing the amount of hepatitis B disease in Italy. *Viral J*. 2008;5:84.
- Cavuslu S, Birinci I, Oncul O, Emekdas G, Erdemoglu A. The Comparison Of Different Recombinant Hepatitis-B Vaccines. *The Internet Journal of Infectious Diseases*. 2003;2(2):7-8.
- Van Damme P, Kane M, Meheus A. Integration of hepatitis B vaccination into national immunisation programmes. Viral Hepatitis Prevention Board. *BMJ*. 1997 Apr 5;314(7086):1033-6.
- Kane MA. Status of hepatitis B immunization programmes in 1998. *Vaccine*. 1998 Nov;16 Suppl:S104-8.
- Brayden RM, Pearson KA, Jones JS, Renfrew BL, Berman S. Effect of thimerosal recommendations on hospitals' neonatal hepatitis B vaccination policies. *J Pediatr*. 2001 May;138(5):752-5.
- Hussain Z, Ali SS, Husain SA, Raish M, Sharma DR, Kar P. Evaluation of immunogenicity and reactogenicity of recombinant DNA hepatitis B vaccine produced in India. *World J Gastroenterol*. 2005 Dec 7;11(45):7165-8.
- Clark SJ, Cabana MD, Malik T, Yusuf H, Freed GL. Hepatitis B vaccination practices in hospital newborn nurseries before and after changes in vaccination recommendations. *Arch Pediatr Adolesc Med*. 2001 Aug;155(8):915-20.
- Jones CD, Page M, Bacon A, Cahill E, Bentley M, Chatfield SN. Characterization of the T- and B-cell immune response to a new recombinant pre-S1, pre-S2 and SHBs antigen containing hepatitis B vaccine (Hepagene); evidence for superior anti-SHBs antibody induction in responder mice. *J Viral Hepat*. 1998 Nov;5 Suppl 2:5-8.
- Alavian SM. Ministry of Health in Iran Is Serious about Controlling Hepatitis B. *Hepat Mon*. 2007;7:3-5.
- Ghorbani GAH. Long-Term Protection of Hepatitis ? Vaccine in Adult. *J Med Sci*. 2007;7(7):1214-7.
- Shokri F, Jafarzadeh A. High seroprotection rate induced by low doses of a recombinant hepatitis B vaccine in healthy Iranian neonates. *Vaccine*. 2001 Aug 14;19(31):4544-8.
- Mansour-Ghaneai F, Fallah MS, Jafarshad R, Joukar F, Arami M, Ale-esmaeil A, *et al*. The Immunologic Response to Anti-Hepatitis B Vaccination Among Medical Students of Guilan University of Medical Sciences, Guilan, Iran. *Hepatitis Monthly*. 2006;6(2):63-666.
- Baldy JL, de Lima GZ, Morimoto HK, Reiche EM, Matsuo T, de Mattos ED, *et al*. Immunogenicity of three recombinant hepatitis B vaccines administered to students in three doses containing half the antigen amount routinely used for adult vaccination. *Rev Inst Med Trop Sao Paulo*. 2004 Mar-Apr;46(2):103-7.
- ul-Haq N, Hasnain SS, Umar M, Abbas Z, Valenzuela-Silva C, Lopez-Saura P. Immunogenicity of 10 and 20 microgram hepatitis B vaccine in a two-dose schedule. *Vaccine*. 2003 Jul 4;21(23):3179-85.
- Cardell K, Akerlind B, Sallberg M, Fryden A. Excellent response rate to a double dose of the combined hepatitis A and B vaccine in previous nonresponders to hepatitis B vaccine. *J Infect Dis*. 2008 Aug 1;198(3):299-304.
- Zhang H, Ma JX, Gong XH, Liu LR, Wu K, Luo FJ, *et al*. [Observation on two kinds of recombinant hepatitis B vaccines used in populations with different immunity]. *Zhonghua Liu Xing Bing Xue Za Zhi*. 2006 Aug;27(8):690-3.
- van der Sande MA, Mendy M, Waight P, Doherty C, McConkey SJ, Hall AJ, *et al*. Similar long-term vaccine efficacy of two versus three doses of HBV vaccine in early life. *Vaccine*. 2007 Feb 9;25(8):1509-12.
- Janbakhsh A, Sayad B, Vaziri S, Aieni P. Serologic response to hepatitis B vaccine in health care workers, Kermanshah, Iran. *Journal of Research in Medical Sciences*. 2006;10(3):147.
- Sharifi MR, Ghorieshian SM. Evaluation of effect of hepatitis B vaccination in HCW in university of shahid Sadooghi, Yazd. *Journal of Shahid Sadooghi University* 1998;5(1): 10.14.
- Das K, Gupta RK, Kumar V, Kar P. Immunogenicity and reactogenicity of a recombinant hepatitis B vaccine in subjects over age of forty years and response of a booster dose among nonresponders. *World J Gastroenterol*. 2003 May;9(5):1132-4.
- Emir S, Buyukpamuk M, Akyuz C, Kutluk T, Guler E, Caglar K. The comparison of antibody response to different hepatitis b vaccines with and without pre-S2 antigen in children with cancer. *Pediatr Hematol Oncol*. 2002 Jun;19(4):227-33.
- Sapru A, Kulkarni PS, Bhav S, Bavdekar A, Naik SS, Pandit AN. Immunogenicity and reactogenicity of two recombinant hepatitis B vaccines in small infants: a randomized, double-blind comparative study. *J Trop Pediatr*. 2007 Oct;53(5):303-7.
- Ghorbani GA, Alavian SM, Ghadimi HR. Long term effects of one or two doses of hepatitis B vaccine in adults after five years. *Pak J Biol Sci*. 2008 Feb 15;11(4):660-3.
- Shi J, Wang X, Wang G, Xu Z, Yang Z, Zheng L, *et al*. [Immunogenicity and safety of recombinant yeast-derived hepatitis B vaccine in adults]. *Zhonghua Yu Fang Yi Xue*

- Za Zhi*. 2002 Nov;**36**(6):366-9.
26. Chen CC, Yen CH, Wu WY, Hu SW, Chen SC, Bell WR, *et al*. Epidemiology of hepatitis B virus infection among young adults in Taiwan, China after public vaccination program. *Chin Med J (Engl)*. 2007 Jul 5;**120**(13):1155-8.
 27. Martins RM, Bensabath G, Arraes LC, Oliveira Mde L, Miguel JC, Barbosa GG, *et al*. Multicenter study on the immunogenicity and safety of two recombinant vaccines against hepatitis B. *Mem Inst Oswaldo Cruz*. 2004 Dec;**99**(8):865-71.
 28. Kulkarni PS, Raut SK, Patki PS, Phadke MA, Jadhav SS, Kapre SV, *et al*. Immunogenicity of a new, low-cost recombinant hepatitis B vaccine derived from *Hansenula polymorpha* in adults. *Vaccine*. 2006 Apr 24;**24**(17):3457-60.
 29. Fabrizi F, Andrulli S, Bacchini G, Corti M, Locatelli F. Intradermal versus intramuscular hepatitis b re-vaccination in non-responsive chronic dialysis patients: a prospective randomized study with cost-effectiveness evaluation. *Nephrol Dial Transplant*. 1997 Jun;**12**(6):1204-11.
 30. Akram DS, Maqbool S, Khan DS, Jafri R, Randhawa S, Valenzuela-Silva C, *et al*. Immunogenicity of a recombinant, yeast-derived, anti-hepatitis-B vaccine after alternative dosage and schedule vaccination in Pakistani children. *Vaccine*. 2005 Dec 30;**23**(50):5792-7.
 31. Rebedea I, Diaconescu IG, Bach D, Bartelsen O, Arndtz N. Comparison of thiomersal-free and thiomersal-containing formulations of a recombinant hepatitis B vaccine (Hepavax-Gene) in healthy adults. *Vaccine*. 2006 Jun 19;**24**(25):5320-6.